Aclaris Therapeutics (NASDAQ:ACRS) Shares Down 7.3% After Analyst Downgrade

Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) traded down 7.3% during trading on Tuesday after Canaccord Genuity Group lowered their price target on the stock from $13.00 to $12.00. Canaccord Genuity Group currently has a buy rating on the stock. Aclaris Therapeutics traded as low as $3.34 and last traded at $3.3450. Approximately 1,921,403 shares changed hands during trading, a decline of 15% from the average daily volume of 2,252,027 shares. The stock had previously closed at $3.61.

Other equities analysts have also recently issued research reports about the company. Craig Hallum set a $9.00 price target on Aclaris Therapeutics in a research note on Wednesday, October 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday, September 21st. Wall Street Zen raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 24th. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Aclaris Therapeutics in a report on Wednesday, October 28th. Finally, Wedbush downgraded shares of Aclaris Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $8.00 to $3.00 in a research report on Tuesday. Three investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Aclaris Therapeutics presently has an average rating of “Buy” and an average price target of $10.67.

Read Our Latest Stock Report on Aclaris Therapeutics

Top Aclaris Therapeutics Stories

These are some of the ACRS stories that stood out recently:

  • Positive Sentiment: Aclaris initiated a Phase 2b trial of modzatinib for moderate-to-severe lichen planus, a condition with no FDA-approved targeted treatments. The FDA has granted the drug Fast Track status; initial results from the oral-disease cohort are expected in the second half of 2027. Aclaris initiates Phase 2b modzatinib trial
  • Neutral Sentiment: Canaccord lowered its price target to $12 from $13 but kept a Buy rating, signaling continued optimism despite the reduced forecast. Canaccord rating update
  • Negative Sentiment: Aclaris said its Phase 2 ADMIRATION trial of bosakitug for atopic dermatitis failed to meet its primary endpoint. The company plans to prioritize other programs, but the result weakens the outlook for this candidate and was a key reason for the stock’s decline. Bosakitug Phase 2 results

Institutional Trading of Aclaris Therapeutics

Large investors have recently made changes to their positions in the stock. Sei Investments Co. bought a new stake in shares of Aclaris Therapeutics during the first quarter valued at approximately $814,000. Bank of New York Mellon Corp bought a new position in Aclaris Therapeutics in the 2nd quarter worth approximately $1,495,000. Dimensional Fund Advisors LP raised its position in Aclaris Therapeutics by 88.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 511,461 shares of the biotechnology company’s stock worth $1,914,000 after purchasing an additional 240,611 shares during the last quarter. Palo Alto Investors LP bought a new position in Aclaris Therapeutics in the 2nd quarter worth approximately $8,535,045. Finally, Deutsche Bank AG acquired a new position in Aclaris Therapeutics during the 2nd quarter worth $5,507,000. Institutional investors own 98.34% of the company’s stock.

Aclaris Therapeutics Trading Down 7.3%

The stock has a market cap of $530.56 million, a price-to-earnings ratio of -5.80 and a beta of 0.96. The firm has a fifty day simple moving average of $4.38 and a 200-day simple moving average of $4.53.

Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.04. The business had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $1.27 million. Aclaris Therapeutics had a negative return on equity of 59.19% and a negative net margin of 1,244.09%. On average, equities analysts predict that Aclaris Therapeutics, Inc. will post -0.56 earnings per share for the current fiscal year.

About Aclaris Therapeutics

(Get Free Report)

Aclaris Therapeutics is a biopharmaceutical company focused on discovering and developing treatments for immuno-inflammatory diseases. Its research programs include small-molecule therapies designed to target pathways involved in inflammation and immune responses. The company’s development portfolio has included candidates for dermatologic and other inflammatory conditions. Aclaris previously developed ESKATA, a topical treatment for raised seborrheic keratoses that received U.S. regulatory approval in 2017.

Read More

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.